EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas.
about
Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutationsMutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature reviewResearch Progress of Mechanisms on Intracranial Metastasis of Non-small Cell Lung Cancer after Clinical Benefit from EGFR-TKIOptimal therapeutic strategy for non-small cell lung cancer with mutated epidermal growth factor receptorTumour Heterogeneity: The Key Advantages of Single-Cell AnalysisTracking genomic cancer evolution for precision medicine: the lung TRACERx studyThe causes and consequences of genetic heterogeneity in cancer evolutionHigh efficiency vortex trapping of circulating tumor cells.The assessment of tumor response by measuring the single largest lesion per organ in metastatic tumors: a pooled analysis of previously reported data.Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations.Liquid biopsy genotyping in lung cancer: ready for clinical utility?Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis?The quest to overcome resistance to EGFR-targeted therapies in cancer.Are all cancer stem cells created equal?A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistryTumor heterogeneity at protein level as an independent prognostic factor in endometrial cancer.Detection of the epidermal growth factor receptor, amphiregulin and epiregulin in formalin-fixed paraffin-embedded human placenta tissue by matrix-assisted laser desorption/ionization mass spectrometry imaging.Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC.Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung AdenocarcinomaThe Prognostic Value of the Tumor Shrinkage Rate for Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Receiving Gefitinib.Interpretation of a heterogeneous radiological response as tumor heterogeneity or a non-tumor diagnosis: A case report.Comparison of EGFR mutation status between plasma and tumor tissue in non-small cell lung cancer using the Scorpion ARMS method and the possible prognostic significance of plasma EGFR mutation statusFeasibility of computed tomography-guided core needle biopsy in producing state-of-the-art clinical management in Chinese lung cancer.Clinical outcome of epidermal growth factor receptor-tyrosine kinase inhibitors therapy for patients with overlapping kirsten rat sarcoma 2 viral oncogene homolog and epidermal growth factor receptor gene mutationsFrom targets to targeted therapies and molecular profiling in non-small cell lung carcinoma.EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation.Guideline Recommendations for EGFR Mutation Testing in Lung Cancer: Proposal of the Korean Cardiopulmonary Pathology Study GroupTumor response assessment by the single-lesion measurement per organ in small cell lung cancer.High concordance of ALK rearrangement between primary tumor and paired metastatic lymph node in patients with lung adenocarcinoma.Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkersUsefulness of conventional transbronchial needle aspiration in the diagnosis, staging and molecular characterization of pulmonary neoplasias by thin-prep based cytology: experience of a single oncological instituteReduced genomic tumor heterogeneity after neoadjuvant chemotherapy is related to favorable outcome in patients with esophageal adenocarcinoma.Surgery for NSCLC in the era of personalized medicine.Implications of intratumour heterogeneity for treatment stratification.Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutationCommon EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors.Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides.Multiparametric Analysis of the Tumor Microenvironment: Hypoxia Markers and Beyond.TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib.EGFR mutation heterogeneity and mixed response to EGFR tyrosine kinase inhibitors of non small cell lung cancer: a clue to overcoming resistance
P2860
Q26744339-B14D50C9-FF2D-44B0-BA25-976B202A6E2BQ26785713-993F85A5-605F-4281-AF6D-3AE19A2BDFD4Q26798043-40DB06D5-D8EE-4C1A-98E7-3E2938E20D30Q26859993-A73D6E83-7CBA-4A12-9655-7FAD17ABE52CQ28066914-A7F58AFA-027E-43BD-B4BE-37AC49352B79Q28655985-EF16977D-6728-4E7C-B439-4986527B42FEQ29615848-76A096A5-DCB5-4CCC-939B-FDE6787C4A4FQ30367788-59D349A7-4CD3-41E7-95D5-CCF6FB203E1CQ30882874-BE2AC7DF-473B-4987-828A-BBD48B252144Q33419961-783E939C-0842-427B-AA53-5AFFFE547885Q33567037-1B8777C7-8155-4F79-B5D3-E22919366E71Q33700689-3627A71D-6B3E-4FB5-9958-2AAA9B9F3B25Q33725976-8AF1525D-867F-4AF3-B235-7E4053E9368BQ34273110-9A438C36-FB8D-41CE-AE74-664127FCA798Q34405695-A08424AC-3662-4286-92A1-D28274CDEF45Q34478381-40FF086C-714D-4B13-9898-3BDA8F1DB333Q34809415-B8B8EC3C-6949-45F4-95E8-4AD667818801Q35034044-880402FC-8965-4B6D-AB12-3734B43B8908Q35793656-9042817A-4834-4F39-A72A-FE0AA815C0DFQ36205477-D668584A-11C4-4431-B5D4-45BA80BCBF42Q36335786-E964464A-6AC8-4011-8C16-AFC1C280B2DDQ36375343-8BD8FB85-7E00-4D3D-A840-8EE2A29DD815Q36439363-A9DA9C22-E9D3-4A9A-8469-DF5FD81986FDQ36477762-738AB38C-10D5-4978-8696-52E3A2B4AEC3Q36615755-5D96CBD0-9B44-4B77-876A-1C38CD51B86FQ36619212-E6447600-2498-4C46-88A3-EB959F74FE85Q36824366-581441D7-AA42-4AAB-A3F6-F38B6B84A34AQ36897213-099BDD76-5FD9-40A7-8181-05F3D900A781Q36948934-8B3D530C-E708-41A6-9783-32E242102EAAQ36962487-39886EF8-0BC1-4310-A7E2-AF408E253961Q37208817-7168DCD4-0D61-4FA6-90D1-546AEEDD6C36Q37536791-FE5A19C8-1B52-4CAD-9854-F8D3FFB16B68Q38084427-C3FF1FCC-8519-4596-836D-D43A70B3FA91Q38151633-9A57C3F5-3152-43C8-8550-2CDF0B7256D7Q38258749-4F277064-6B01-4CB5-8590-A88483C69AFDQ38335360-55CD8BEB-D0F4-4FF3-811A-975730A81915Q38398139-C62059BD-EBF8-4FFD-AEF8-F735F95593C8Q38689978-63673B64-6CF4-466B-9B22-E47593176EC5Q38853578-5EBABB20-6DE9-4170-9206-39689EB59642Q41166613-06B05343-8138-4B36-BF2A-FE3BD68DC86F
P2860
EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
EGFR mutation heterogeneity an ...... itors of lung adenocarcinomas.
@ast
EGFR mutation heterogeneity an ...... itors of lung adenocarcinomas.
@en
type
label
EGFR mutation heterogeneity an ...... itors of lung adenocarcinomas.
@ast
EGFR mutation heterogeneity an ...... itors of lung adenocarcinomas.
@en
prefLabel
EGFR mutation heterogeneity an ...... itors of lung adenocarcinomas.
@ast
EGFR mutation heterogeneity an ...... itors of lung adenocarcinomas.
@en
P2093
P2860
P1433
P1476
EGFR mutation heterogeneity an ...... bitors of lung adenocarcinomas
@en
P2093
Ben-Yuan Jiang
Hong-Hong Yan
Hua-Jun Chen
Jin-Ji Yang
She-Juan An
Wen-Zhao Zhong
Xu-Chao Zhang
Xue-Ning Yang
P2860
P304
P356
10.1634/THEONCOLOGIST.2011-0385
P577
2012-06-06T00:00:00Z